Alameda Biotech Firm to Be Recognized

Singulex, which develops and manufactures a test for the early detection of cardiovascular disease out of its Harbor Bay offices, is a finalist for this year’s East Bay Innovations Awards.

The East Bay Economic Development Alliance will toast Singulex and 15 other innovators at a Feb. 13 gala at the Fox Theater in Oakland.

“All of us at Singulex are deeply honored to be considered for this award,” said President & CEO Guido Baechler, in a press release. “It means a great deal to us to be recognized for our pioneering work in cardiovascular diagnostics, which is helping to reduce the chances of future heart attacks for millions of people. Our location in Alameda has enabled us to attract and retain bright, innovative talent, and has been an important part of our success.”

“The City of Alameda congratulates Singulex on this distinction,” said Debbie Potter, the City’s Community Development Director, in a statement. “It is exciting to see Singulex get the recognition it deserves for its extremely sophisticated and profoundly essential work.”

Singulex is a finalist for the East Bay Innovation Award in the life sciences, which was given to Harbor Bay-based Penumbra, last year. (Penumbra’s work focuses on strokes and vascular disease, and it employs over 400 people worldwide.)

Janet Levaux